Trial reportScientific reports2025
Clinical and dermoscopic assessment of the efficacy of topical trichloroacetic acid 70% versus methoxsalen 0.2% paint in stable acral vitiligo.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hydrogen peroxide 40% versus trichloroacetic acid 70% in the treatment of seborrheic keratosis.Wiener medizinische Wochenschrift (1946) · 2026Trial
- Comparative Efficacy of Topical Trichloroacetic Acid and Superficial Cryotherapy in Resistant Alopecia Areata: A Randomized Clinical Trial.The Journal of clinical and aesthetic dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Loss and absence of melanocytes due to a number of factors is responsible for vitiligo; known to be the commonest disorder of pigmentation. The aim of the study was to assess clinically and dermoscopically the efficacy of topical trichloroacetic acid 70% versus methoxsalen 0.2% paint in stable acral vitiligo. The patients were randomly divided into 2 groups. Group a (n = 35) received topical 0.2% methoxsalen every other day for 4 months duration with dermoscopic follow up while group b (n = 35) received received topical TCA 70% application at the clinic every two weeks for 4 months with dermoscopic follow up. The majority of subjects in both groups experienced either no or mild improvement. In TCA group, mean improvement was 4.0 ± 11.6% with range of 0-60% while in the methoxsalen group, mean improvement was 0.57 ± 3.3% with range of 0-20% (p = 0.051). The majority of patients reported poor satisfaction. Both modalities did not demonstrate a significant clinical nor dermoscopic response. TCA 70% had a lower effective rate than other studies probably due to resistance of acral vitiliginous lesions to treatment in comparison to other sites of the body. Further larger multi centre studies with different concentration and combination modalities are required to detect promising treatments for vitligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.